Capivasertib is under clinical development by AstraZeneca and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Capivasertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Capivasertib overview

Capivasertib (Truqap) belongs to alpha amino acid amides acts as anti-cancer agent. It is formulated as film coated tablets for oral route of administration. Truqap in combination with fulvestrant is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations.

Capivasertib (AZD-5363) is under development for the treatment of relapsed or refractory (R/R) B-cell non-Hodgkin's lymphomas, relapsed/refractory B-cell non-Hodgkin's lymphoma, advanced refractory lymphoma and multiple myeloma, solid tumors including metastatic triple negative breast cancer, advanced (inoperable) or metastatic HR+/HER2− breast cancer, HER2 positive breast cancer, hormone refractory castration resistant prostate cancer, metastatic hormone-sensitive prostate cancer, adenocarcinoma of prostate cancer, recurrent endometrial cancer, non-small cell lung cancer, ovarian cancer, primary peritoneal cancer and fallopian tube cancer. The drug candidate is administered through oral route as a tablet. It is a pyrrolopyrimidine-derived compound that targets all isoforms of AKT (protein kinase B). It was also under development for cervical cancer, follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL).

AstraZeneca overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

For a complete picture of Capivasertib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.